Victory Capital Management Inc. Sells 22,235 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Victory Capital Management Inc. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 25.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,521 shares of the medical research company's stock after selling 22,235 shares during the period. Victory Capital Management Inc.'s holdings in IQVIA were worth $11,728,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in IQV. Continuum Advisory LLC increased its holdings in shares of IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares during the period. Ballentine Partners LLC boosted its stake in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after purchasing an additional 69 shares during the period. ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. Zions Bancorporation N.A. grew its position in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the period. Finally, Quadrant Capital Group LLC increased its stake in shares of IQVIA by 10.7% in the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after buying an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.8%

Shares of IQVIA stock traded down $1.65 during trading on Friday, reaching $199.17. The stock had a trading volume of 2,138,911 shares, compared to its average volume of 2,043,734. The company has a current ratio of 0.84, a quick ratio of 0.82 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $33.86 billion, a price-to-earnings ratio of 28.82, a P/E/G ratio of 2.29 and a beta of 1.30. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The stock has a fifty day moving average price of $155.96 and a two-hundred day moving average price of $170.53.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the prior year, the firm posted $2.64 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IQV. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research note on Wednesday. Barclays increased their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Redburn Partners set a $188.00 price objective on IQVIA in a report on Friday, May 23rd. Finally, William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.